gealadenocarcinomas.BrJCancer,1999,79(3-4):595-603.14KennedyS.Proteomicprofilingfromhumansamples:thebodyfluidalternative.ToxicolLett,2001,120(1-3):379-384.15PrasannanL,MisekDE,HindererR,etal.Identificationofbeta-tubulinisoformsastumourantigensinneuroblastoma.ClinCancerRes,2000,6(10):3949-3956.16WulfkuhleJD,SgroiDC,KrutzschH,etal.Proteomicsofhumanbreastductalcarcinormainsitu.CancerRes,2002,62(22):6740-6749.17LeNaourF,MisekDE,KrauseMC,etal.Proteomics-basedidentificationofRSPDJ-1asanovelcirculatingtumorantigeninbreastcancer.ClinCancerRes,2001,7(11):3328-3335.18ChumanY,BergmanA,UenoT,etal.NapsinA,amemberoftheasparticproteasefamily,isabundantlyexpressedinnormallungandkidneytissueandisexpressedinlungadenocarcinomas.FEBSLett,1999,462(1-2):129-134.19JonesMB,KrutzschH,ShuH,etal.Proteomicanalysisandidentificationofnewbiomarkersandtherapeutictargetsforinvasiveovariancancer.Proteomics,2002,2(1):76-84.20MullerEC,SchumannM,RickersA,etal.StudyofBurkittlym-phomacelllineproteinsbyhighresolutiontwo-dimensionalgelelec-trophoresisandnanoelectrospraymassspectrometry.Electrophore-sis,1999,20(2):320-330.21ThiesingJT,OhnoJonesS,KolibataKS,etal.EfficacyofSTI571,anABLtyrosinekinaseinhibitor,inconjunctionwithotherantileukemicagentsagainstBCR-ABL-positivecells.Blood,2000,96(9):3195-3199.22NormannoN,CampiglioM,DeLA,etal.CooperativeinhibitoryeffectofZD1839(Iressa)incombinationwithtrastuzumab(Her-ceptin)onhumanbreastcancercellgrowth.AnnOncol,2002,13(1):65-72.23PetricoinEF,ArdekaniAM,HittBA,etal.Useofproteomicpatternsinserumtoidentifyovariancancer.Lancet,2002,359(9603):572-577.24AdamBL,QuY,DavisJW,etal.Serumproteinfingerprintingcoupledwithapattern-matchingalgorithmdistinguishesprostatecancerfrombenignprostatehyperplasiaandhealthymen.CancerRes,2002,62(13):3609-3614.25LiJ,ZhangZ,RosenzweigJ,etal.Proteomicsandbioinformaticsapproachesforidentificationofserumbiomarkerstodetectbreastcancer.ClinChem,2002,48(8):1296-1304.(收稿日期:2003-09-09修回日期:2003-11-16)作者单位:200433上海,第二军医大学海军医学系放射医学教研室MDM2功能及其调控机制黄越承综述蔡建明审校摘要MDM2是调节p53通路的重要基因,具有降解p53及泛素化的功能,参与肿瘤的发生、发展,并与胚胎发育和组织分化相关。近年来对MDM2的分子作用机制和调控机制的研究取得了一定进展,已用MDM2反义寡核苷酸进行肿瘤的基因治疗。现对MDM2基因的功能及其表达调控机制的研究进展予以综述。关键词癌基因;调控机制中图分类号R730.231文献标识码A文章编号1000-8225(2004)05-0336-04MDM2基因是一原癌基因,编码蛋白总分子量为90kD,因mRNA的不同剪切可形成多种不同分子量的变异体,如p57、p64、p85、p90等。MDM2是p53调控网络中的下游基因,作为p53的重要调节因子,参与细胞生长抑制、凋亡、细胞周期调控等过程。MDM2与p53构成降解-反式激活循环通路。MDM2具有泛素化-蛋白酶降解p53的功能,而p53反式激活因子又可诱导MDM2,消除反馈循环。p53-MDM2模式是癌蛋白-抑癌蛋白的典型作用模式。p53的2个自动反馈循环,即B-连环蛋白和蛋白激酶B(PKB)循环,其关键点在于p53与MDM2的相互作用。MDM2能使p53钝化并经蛋白酶降解,B-连环蛋白使MDM2失活,导致p53堆积;而p53反过来又反馈抑制B-连环蛋白。PKB能阻断p53活化,激活MDM2,而p53又可使PKB减少。最终结果取决于各种组分之间的平衡及其他信号途径的调节。MDM2基因突变或表达异常将导致平衡的破坏,可能与细胞转化和肿瘤发生有关[1]。1生物学功能对低剂量电离辐射的研究发现,低剂量率照射能导致某些基因诱导表达模式的改变,从而起到对生物组织的保护性作用;但在接受2~50cGyX线#336#国外医学肿瘤学分册2004年5月第31卷第5期ForeignMedSciOncolSect,May2004,Vol.31,N...
VIP
